The Venture Codex Logo

The Venture Codex

Arix Bioscience

20 Berkeley Square, Mayfair, London, W1J 6EQ, United Kingdom

Overview

Global venture capital firm investing in biotechnology startups.

Founded

2015

Deals ยท 12mo

0

Links

WebsiteLinkedInX (Twitter)

Stage focus

Series A
Series B
Series C

Geographic focus

Israel
United Kingdom
United States

Sector focus

Biotechnology
Finance
Health Care
Venture Capital

Investment portfolio

29rounds
NAMEDATESIZE
Evommune
Apr 2023Led
$50 MSeries B
Ensoma
Jan 2023Led
$85 MSeries B
Sorriso Pharmaceuticals
Dec 2021Led
$31 MSeries A
Depixus
Dec 2021Participated
$35 MSeries A
Disc Medicine
Sep 2021Participated
$90 MSeries B
Artios Pharma
Jul 2021Participated
$152 MSeries C
Artios
Jul 2021Participated
$152 MSeries C
Pyxis Oncology
Mar 2021Led
$152 MSeries B
Aura Biosciences
Mar 2021Participated
$80 MOther Equity
VelosBio
Jul 2020Participated
$137 MSeries B
Amplyx Pharmaceuticals
May 2020Participated
$53 MSeries C
Quench Bio
Jan 2020Participated
$50 MSeries A
Evommune
Apr 2023Led
$50 MSeries B
Ensoma
Jan 2023Led
$85 MSeries B
Sorriso Pharmaceuticals
Dec 2021Led
$31 MSeries A
Depixus
Dec 2021Participated
$35 MSeries A
Disc Medicine
Sep 2021Participated
$90 MSeries B
Artios Pharma
Jul 2021Participated
$152 MSeries C
Artios
Jul 2021Participated
$152 MSeries C
Pyxis Oncology
Mar 2021Led
$152 MSeries B
Aura Biosciences
Mar 2021Participated
$80 MOther Equity
VelosBio
Jul 2020Participated
$137 MSeries B
Amplyx Pharmaceuticals
May 2020Participated
$53 MSeries C
Quench Bio
Jan 2020Participated
$50 MSeries A
29
Items
...
Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

Arix Bioscience: 29 funding rounds are recorded in the selected participation categories.All available history.
Arix Bioscience: 29 funding rounds are recorded in the selected participation categories. All available history
Round typeLed dealsParticipated deals
Series A35
Series B83
Series C+36
Other Equity01

Monthly Deal Activity

Arix Bioscience: 29 deals are recorded across 122 months.All available history.
Arix Bioscience: 29 deals are recorded across 122 months. All available history
MonthDeals
Sep '161
Oct '160
Nov '160
Dec '160
Jan '170
Feb '170
Mar '170
Apr '170
May '173
Jun '172
Jul '171
Aug '171
Sep '171
Oct '170
Nov '170
Dec '172
Jan '180
Feb '180
Mar '180
Apr '180
May '180
Jun '180
Jul '180
Aug '181
Sep '180
Oct '181
Nov '181
Dec '180
Jan '190
Feb '190
Mar '191
Apr '191
May '190
Jun '190
Jul '190
Aug '190
Sep '191
Oct '190
Nov '190
Dec '190
Jan '201
Feb '200
Mar '200
Apr '200
May '201
Jun '200
Jul '201
Aug '200
Sep '200
Oct '200
Nov '200
Dec '200
Jan '210
Feb '210
Mar '212
Apr '210
May '210
Jun '210
Jul '212
Aug '210
Sep '211
Oct '210
Nov '210
Dec '212
Jan '220
Feb '220
Mar '220
Apr '220
May '220
Jun '220
Jul '220
Aug '220
Sep '220
Oct '220
Nov '220
Dec '220
Jan '231
Feb '230
Mar '230
Apr '231
May '230
Jun '230
Jul '230
Aug '230
Sep '230
Oct '230
Nov '230
Dec '230
Jan '240
Feb '240
Mar '240
Apr '240
May '240
Jun '240
Jul '240
Aug '240
Sep '240
Oct '240
Nov '240
Dec '240
Jan '250
Feb '250
Mar '250
Apr '250
May '250
Jun '250
Jul '250
Aug '250
Sep '250
Oct '250
Nov '250
Dec '250
Jan '260
Feb '260
Mar '260
Apr '260
May '260
Jun '260
Jul '260
Aug '260
Sep '260
Oct '260

Sector Breakdown

Arix Bioscience: Health & Life Sciences is the largest displayed sector by deal count (27 deals).All available history.

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

Arix Bioscience: Health & Life Sciences is the largest displayed sector by deal count (27 deals). All available history
SectorDeals
Health & Life Sciences27
Marketing & Advertising1
Professional Services1
Data, Analytics & IT1

Deal Size Distribution

Arix Bioscience: 29 rounds have a disclosed size in the displayed size bands.All available history.

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

Arix Bioscience: 29 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)Deals
<$5M0
$5M-$10M0
$10M-$25M2
$25M-$50M9
$50M-$100M14
$100M-$250M4
$250M-$500M0
$500M-$1B0
$1B+0

Deals By Geography

Arix Bioscience: United States has the largest recorded deal count among the displayed regions (18 deals).All available history.

Top 4 of 4 regions; European countries are grouped as Europe.

Arix Bioscience: United States has the largest recorded deal count among the displayed regions (18 deals). All available history
RegionDeals
United States18
Europe8
Israel2
Canada1
Arix Bioscience: 20 co-investors are shown, with Lundbeckfond Ventures sharing 7 recorded deals.All available history.

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

Arix Bioscience: 20 co-investors are shown, with Lundbeckfond Ventures sharing 7 recorded deals. All available history
Co-investorShared deals
Lundbeckfond Ventures7
OrbiMed7
Sofinnova Ventures6
Advent Life Sciences5
Cormorant Asset Management5
Pfizer Ventures5
Alexandria Venture Investments4
Andera Partners4
Chiesi Ventures4
EQT Life Sciences (LSP)4
New Enterprise Associates4
New Leaf Venture Partners4
SV Health Investors4
AbbVie Ventures3
Adage Capital Management3
Bay City Capital3
Columbus Venture Partners3
Janus Henderson Investors3
M Ventures3
Pappas Capital3

Investment Strategy

Arix Bioscience: Led accounts for 48% and participating for 52% of round participation.All available history.
Arix Bioscience: Led accounts for 48% and participating for 52% of round participation. All available history
CategoryDeals (count)Share (%)
Led1448%
Participating1552%
Arix Bioscience: Single-lead accounts for 36% and co-led for 64% of lead dynamics.All available history.
Arix Bioscience: Single-lead accounts for 36% and co-led for 64% of lead dynamics. All available history
CategoryDeals (count)Share (%)
Single-lead536%
Co-led964%

Team

Angela Ene

Interim Finance Director

Christian Schetter

Managing Director

Daniel O'Connell

Investment Manager

James Rawlingson

Chief Financial Officer

Joe Anderson

Chief Investment Officer

Jonathan Tobin

Managing Director

Mark Chin

Investment Manager

Robert Lyne

Chief Executive Officer